Clinical trial
Phase Ib Trial Of Pembrolizumab And Nintedanib
NCT02856425 is registered in ClinicalTrials.gov with Gustave Roussy, Cancer Campus, Grand Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase Ib Trial Of Pembrolizumab And Nintedanib
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- November 10, 2016
- Completion date
- January 10, 2026
- Enrollment
- 196 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.
patients with any advanced solid tumors